摘要
目的研究贝伐单抗对肺癌胸腔积液模型小鼠血管生成及相关细胞因子的影响。方法按照体重将小鼠随机分为5组,每组10只:正常组、模型组、顺铂组、贝伐单抗组、联合组。用胸腔注射Lewis肺癌细胞建立肺癌恶性胸腔积液小鼠模型(正常组除外)。模型组腹腔注射0.9%Na Cl 0.4 m L;顺铂组腹腔注射顺铂5 mg·kg^(-1);贝伐单抗组腹腔注射贝伐单抗15 mg·kg-1;联合组腹腔注射贝伐单抗和顺铂(15 mg·kg^(-1)+5 mg·kg^(-1))。均每周2次,连续给药2周。比较2组小鼠的生存时间、胸腔积液量;用酶联免疫吸附法检测白细胞介素-2(IL-2)、血管内皮生长因子A(VEGF-A)的含量。结果给药后,模型组、顺铂组、贝伐单抗组和联合组的小鼠生存时间分别为(11.76±1.34),(14.35±1.56),(16.65±2.12),(18.42±2.35)d;这4组的胸腔积液量分别为(1.12±0.24),(0.89±0.20),(0.74±0.22),(0.56±0.25)m L;这4组的VEGF-A含量分别为(625.45±72.52),(454.25±55.14),(265.25±32.21),(205.25±25.54)pg·m L^(-1);这4组的IL-2分别为(70.12±8.45),(56.45±6.52),(130.12±15.45),(110.24±12.36)pg·m L^(-1)。顺铂组、贝伐单抗组和联合组的上述指标与模型组比较,差异有均统计学意义(P<0.05,P<0.01)。结论贝伐单抗有助于减少肺癌恶性胸腔积液模型小鼠胸腔积液量,延长生存时间。
Objective To investigate the effect of bevacizumab on angiogenesis and related cytokines in model mice with malignant pleural effusion（ PE）. Methods The mouse model of lung cancer with malignant PE were established by pleural injection of Lewis lung cancer cells.Mouse were randomly divided into model group,cisplatin group,bevacizumab group,conbination group（ bevacizumab combined with cisplatin）,and health mouse as normal group. Mouse in model group were intraperitoneally injected with 0. 9 % NaCl 0. 4 m L; mouse in cisplatin group were intraperitoneal injected with cisplatin 5 mg ·kg-（-1）; mouse in bevacizumab group was injected with bevacizumab 15 mg ·kg-（-1）; mouse in the combination group were intraperitoneally injected with the two drugs（ 5 mg·kg-（-1）＋ 15 mg·kg-（-1））,2 times per a week for 2 weeks.The survival time and PE in four groups were compared. The contents of vascular endothelial growth factor-A（ VEGF-A）,interleukin-2（ IL-2） in malignant PE of mouse in all groups were detected by enzyme linked immunosorbent assay. Results After dosing,the survival time in mouse of the model group,cisplatin group,bevacizumab group,and combination group were（ 11. 76 ± 1. 34）,（ 14. 35 ± 1. 56）,（ 16. 65 ± 2. 12）,（ 18. 42 ± 2. 35） d,respectively; the a mount of PE in the four groups were（ 1. 12 ± 0. 24）,（ 0. 89 ± 0. 20）,（ 0. 74 ± 0. 22）,（ 0. 56 ± 0. 25） m L respectively. The level of VEGF-A in the four groups were（ 625. 45 ± 72. 52）,（ 454. 25 ± 55. 14）,（ 265. 25 ± 32. 21）,（ 205. 25 ± 25. 54） pg·m L-（-1）,respectively. The level of IL-2 in the four groups were（ 70. 12 ± 8. 45）,（ 56. 45 ± 6. 52）,（ 130. 12 ± 15. 45）,（ 110. 24 ± 12. 36） pg · m L-（-1）,respectively. Comparison between drugs groups and model group on the factors,the differences were significant（ P〈0. 05,P〈0. 01）. Conclusion Bevacizumab can reduce the amount of PE and prolong the survival time of the model mouse with malignant
作者
朱大鹏
郭鹏
俞碧君
周建英
ZHU Da-peng;GUO Peng;YU Bi-jun;ZHOU Jian-ying(Endoscopy center,Zhejiang Tumor Hospital, Hangzhou Zhejiang Tumor 310022, China;Department of Respiration, First Affiliated Hospital of Medical College of Zhejiang University, Hangzhou 310003, China)
出处
《中国临床药理学杂志》
CAS
CSCD
北大核心
2018年第8期942-944,960,共4页
The Chinese Journal of Clinical Pharmacology
基金
浙江省医药卫生科技计划基金资助项目(2011ZDA025)
关键词
肺癌
恶性胸腔积液
贝伐单抗
血管内皮生长因子
免疫
lung cancer
malignant pleural effusion
bevacizumab
vascular endothelial growth factor
immunity
